WCRC Analysis
XBiotech announced on 23 October that Jan-Paul Simard would become co-chief executive alongside Sushma Shivaswamy, effective that day. The company’s announcement describes Shivaswamy’s research and manufacturing experience and Simard’s work in clinical development. It presents their backgrounds as complementary.
That is the company’s rationale for the appointment. The release does not set out a detailed division of authority or a procedure for resolving disagreement. It therefore supports a discussion of the questions shared leadership raises, rather than a verdict on how XBiotech’s arrangement performs.
WCRC’s view is that the quality of a co-CEO model depends heavily on what happens at the boundary between the two roles. A clear boundary gives managers a way to act. An ambiguous one invites them to seek the answer they prefer.
Decide where one answer is required
Some responsibilities can have a single executive owner even within a shared leadership structure. Others require both executives because a choice changes the resources or obligations of the whole business. The organisation should know which is which.
An illustrative case would be a development programme that needs additional funding. Scientific assessment, operating capacity and financial commitments may all be relevant. Dividing the discussion into separate departmental decisions could leave the underlying trade-off unresolved. Requiring two signatures on every routine expense would create a different problem.
A workable arrangement can identify decisions reserved for joint consideration, set a timetable for resolving them and name the route for escalation. The purpose is to give uncertainty somewhere to go. It should not depend on the executives always agreeing informally.
Disagreement can improve a decision when each person tests an assumption the other has missed. It becomes costly when the organisation cannot tell whether a decision is still open. Managers need an authoritative record of the outcome, including the assumptions on which approval rests.
There should also be a rule for communicating a joint decision. Staff should not have to reconcile two accounts of the same instruction. Clear communication protects the executives’ ability to challenge each other privately without exporting unresolved differences into the operating team.
The board must evaluate the shared work
Separate areas of responsibility can make performance easier to assess. They can also allow an important issue to fall between the roles. A board reviewing joint leadership should ask about decisions that required coordination, including those delayed or reopened.
That review needs evidence. Useful material could include the time taken to resolve a reserved decision, whether its assumptions proved sound and whether the executive team received a consistent direction. These are proposed governance questions; they are not metrics disclosed by XBiotech or findings from WCRC research.
The arrangement also needs a plan for absence and succession. If one co-CEO leaves, managers should know how authority changes while the board considers its next step. Shared leadership should be understandable in ordinary conditions and during a disruption.
A co-CEO announcement tells the outside world who holds office. Its practical meaning is established inside the business, through the decisions each executive can make, the decisions they must make together and the process that produces a final answer.
WCRC analysis. The appointment is sourced to XBiotech; the proposed management practices are editorial analysis, not a description of undisclosed company arrangements.